Novartis wins on quantity, but Eli Lilly takes the cake on value of new launches: report

New drugs are a staple of the pharmaceutical industry and a key strategy for drugmakers to deliver long-term growth. But, according to a new report by Evaluate Vantage, quantity doesn’t always trump quality.

While Novartis leads the Big Pharma pack with the most launches over the past five years, Eli Lilly’s new drugs have the most value, Evaluate Vantage reports. Novartis’ 14 new approvals over that timeline rank “thoroughly middle table” in terms of value, according to Evaluate’s analysis. On the flip side, Eli Lilly's Mounjaro has the highest value of any new launch at $27.5 billion.